stockrow
Saturday 7 November 2026
Export PGEN’s income statement to Excel — free account
Precigen, Inc.
PGEN Healthcare Biotechnology
Precigen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.7 million, up 146.7% from fiscal 2024.
- Revenue
- +2,437.6%
- EPS
- +109.4%
- Free cash flow
- +140.3%
- Total debt
- +1.47%
Quarter to September 2026, against a year earlier
4.43
0.21
+4.98%
Follow PGEN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
116.46 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
19.54 | 23.73 | 43.40 | 135.09 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
258.07 | (114.23) | (31.28) | (55.77) | |
P/B ratio |
36.60 | 46.68 | 67.76 | 62.56 | |
Price to Tangible BV |
46.23 | 78.85 | 641.00 | 523.91 | |
EV/Sales |
19.93 | 24.54 | 45.01 | 136.04 | |
EV/EBITDA |
82.36 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(42.73) | (18.43) | (12.33) | (15.00) | |
EV/FCF |
(42.10) | (18.26) | (12.16) | (14.67) | |
Quick Ratio |
4.63 | 3.76 | 3.93 | 2.74 | |
Current Ratio |
5.58 | 4.58 | 4.82 | 3.09 | |
Net Debt/EBITDA |
1.21 | 2.33 | (7.58) | 0.22 | |
Debt/Assets |
44.44% | 55.13% | 67.46% | 59.92% | |
Debt/Equity |
1.12 | 2.15 | 4.62 | 4.46 | |
Asset Turnover |
0.82 | 0.63 | 0.24 | 0.06 | |
Operating CF/Net income |
0.33 | (0.89) | 5.53 | 1.00 | |
Capex/Depreciation |
(0.33) | (0.31) | (0.24) | (0.03) | |
Interest Coverage |
12.90 | 7.67 | (2.06) | (7.31) | |
Research and Development Expense of Revenue |
8.94% | 13.25% | 24.25% | 153.12% | |
Selling, General and Administrative Expense of Revenue |
30.15% | 40.47% | 90.53% | 386.53% | |
Intangible Assets out of Total Assets |
0.08 | 0.10 | 0.13 | 0.12 | |
Share Based Compensation of Revenue |
5.09% | 6.51% | 15.19% | 47.38% | |
Graham Net Nets |
0.01 | 0.00 | (0.01) | (0.01) | |
Graham Number |
0.62 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
0.86% | (19.06%) | (31.95%) | (33.40%) | |
Free Cash Flow Yield |
(2.42%) | (5.66%) | (8.53%) | (6.87%) | |
Revenue per Share |
0.21 | 0.15 | 0.07 | 0.01 | |
Operating CF per Share |
0.03 | (0.05) | (0.12) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.03 | (0.05) | (0.12) | (0.07) | |
Cash per Share |
0.13 | 0.11 | 0.16 | 0.31 | |
Shareholders Equity per Share |
0.23 | 0.12 | 0.06 | 0.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.23 | 0.12 | 0.06 | 0.07 | |
Free Cash Flow |
11.45 | (18.20) | (44.08) | (23.48) | |
Working Capital |
140.97 | 105.03 | 80.57 | 77.93 | |
Capital Expenditures |
(0.43) | (0.39) | (0.26) | (0.02) | |
Net Current Asset Value |
43.45 | 7.66 | (16.72) | (19.36) | |
EV/EBIT |
93.03 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
91.18 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
48.86 | 36.31 | 13.88 | 2.76 | |
Average Payables |
6.66 | 4.61 | 2.85 | 7.76 | |
Average Inventory |
12.99 | 10.27 | 7.47 | 4.90 | |
Average Assets |
191.68 | 136.10 | 133.71 | 150.39 | |
Average Common Equity |
62.83 | 3.40 | 3.09 | 29.71 |
Columns are period end dates · fundamentals updated 6 Nov 2026